Madrigal Pharmaceuticals MDGL shares soared 10.9% on Wednesday. The uptrend was observed after the U.S. Patent and Trademark ...

Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 87.

Investors in Madrigal Pharmaceuticals Inc (Symbol: MDGL) saw new options become available this week, for the June 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up ...

Madrigal (MDGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings ...

Investors in Madrigal Pharmaceuticals Inc (Symbol: MDGL) saw new options become available today, for the January 2025 expiration. One of the key data points that goes into the price an option ...

Madrigal Pharmaceuticals is transitioning from clinical trials to market-ready solutions for non-alcoholic steatohepatitis and liver fibrosis. Read more here.

Madrigal Pharmaceuticals, Inc. (MDGL) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...

Read about Madrigal Pharmaceuticals Inc (MDGL:XNAS) stock and today's latest news and financial updates.